Female Contraceptive — Competitive Intelligence Brief

Female Contraceptive (Female Contraceptive) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormonal contraceptive. Area: Reproductive Health.

marketed Hormonal contraceptive Progesterone receptor, estrogen receptor Reproductive Health Small molecule

Target snapshot

Female Contraceptive (Female Contraceptive) — Italfarmaco. Female contraceptives prevent pregnancy by suppressing ovulation and altering the reproductive tract environment through hormonal mechanisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Female Contraceptive TARGET	Female Contraceptive	Italfarmaco	marketed	Hormonal contraceptive	Progesterone receptor, estrogen receptor
Continuous OC (EE/DROS)	Continuous OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor
Nomegestrol Acetate / Estradiol	Nomegestrol Acetate / Estradiol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, Estrogen receptor
norelgestromin + ethinyl estradiol	norelgestromin + ethinyl estradiol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Combined oral contraceptive (progestin + estrogen)	Progesterone receptor, estrogen receptor
Ortho Tri-Cyclen LO	Ortho Tri-Cyclen LO	Bristol-Myers Squibb	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway
Intermittent OC (EE/DROS)	Intermittent OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormonal contraceptive class)

1. Penn State University · 2 drugs in this class
2. Italfarmaco · 1 drug in this class
3. Kayseri Education and Research Hospital · 1 drug in this class
4. TherapeuticsMD · 1 drug in this class
5. University of Alabama at Birmingham · 1 drug in this class
6. University of Athens · 1 drug in this class
7. FHI 360 · 1 drug in this class
8. University of Pittsburgh · 1 drug in this class